Fundraising Fox
TransEnterix
Morrisville, US · Delaware corporation · 273 employees on LinkedIn · 5 known investors
Find your way into TransEnterix
Sign up to see every warm intro you have to TransEnterix
- Paths you didn't know you had: your email and LinkedIn already hold routes to the TransEnterix team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Asensus Surgical (formerly TransEnterix) develops robotic-assisted surgical systems and augmented intelligence technology, including reusable instruments, to give surgeons real-time information during procedures. Its products serve surgeons and hospitals in the operating room across international markets.
Founders & leadership
AF
Anthony FernandoBoard Member2019–2024Anthony Fernando served as CTO, COO, and CEO of Asensus Surgical (formerly TransEnterix) from 2015 to 2024, leading development of the company's robotic-assisted surgical platform and Performance-Guided Surgery technology through FDA clearance and international deployment. He has technical expertise in AI and machine vision systems for surgical applications and experience building and leading cross-functional global teams.
TM
Todd M. PopePresident and CEO2008–2019Pope led TransEnterix as president and CEO from 2008 to 2019, and later served as executive chairman of UV Innovators and president and CEO of WellAir before joining Revival Healthcare Capital as a senior partner in 2020. He has served on the board of AdvaMed Accel, including as chairman, and on the board of advisors of UNC Chapel Hill's Kenan-Flagler Business School.
JJ
James J. MartinExecutive
CJ
Charles J. FilipiExecutive
JG
Jeffrey G. SpragensExecutive
Board
PA
JH
Jane H. HsiaoBoard director
WJ
William, Jr. N StarlingBoard director
AR
DB
AS
Investors · 5
Aisling Capitallisted by Aisling CapitalNew Yorkvia Aftab Kherani · board
How we know: Aisling Capital's portfolio page · board seat on SEC Form D · funding news · Not right? Tell us
Saints Capitallisted by Saints CapitalDenver
How we know: Saints Capital's portfolio page · Not right? Tell us
SV Health Investorslisted by SV Health InvestorsLondon · $1M – $20Mvia Paul LaViolette · board
How we know: SV Health Investors's portfolio page · board seat on SEC Form D · Not right? Tell us
Quaker BioVenturesreported
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$24.6M disclosed across 4 of 5 rounds · 2011–2021
▶$950KraisedSep 2017 · 1 investors · Other Health CareRule 506(b)
▶$950KraisedSep 2017 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Paul A LaVioletteDirector
- Aftab R KheraniDirector
- Richard, Jr. C PfennigerDirector
- Andrea BiffiDirector
- Todd M PopeExecutive Officer, Director
- David B MilneDirector
- Jane H HsiaoDirector
- Joseph P SlatteryExecutive Officer
- William N KelleyDirector
- Anthony FernandoExecutive Officer
- William, Jr. N StarlingDirector
- Offering amount
- $950K
- Amount sold
- $950K
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$115.7KraisedSep 2016 · 1 investors · Other Health CareRule 506(b)
▶$115.7KraisedSep 2016 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Anthony FernandoExecutive Officer
- Paul A LaVioletteDirector
- Jane H HsiaoDirector
- William N KelleyDirector
- Andrea BiffiDirector
- William, Jr. N StarlingDirector
- Aftab R KheraniDirector
- David B MilneDirector
- Richard, Jr. C PfennigerDirector
- Todd M PopeExecutive Officer, Director
- Joseph P SlatteryExecutive Officer
- Offering amount
- $214.2K
- Amount sold
- $115.7K
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.3MraisedFeb 2012 · 36 investors · Other Health CareRule 506(b)
▶$8.3MraisedFeb 2012 · 36 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Richard Pfenniger, Jr.Director
- James J. MartinExecutive Officer
- Jane H. HsiaoDirector
- Kevin T. WayneDirector
- Charles J. FilipiExecutive Officer, Director
- Chao C. ChenDirector
- Jeffrey G. SpragensExecutive Officer, Director
- Steven D. RubinDirector
- Offering amount
- $8.3M
- Amount sold
- $8.3M
- First sale
- Feb 2012
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
▶$15.2MraisedFeb 2012 · 15 investors · Other Health CareRule 506(b)
▶$15.2MraisedFeb 2012 · 15 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Andrew SchiffDirector
- Paul La VioletteDirector
- John OnopchenkoDirector
- Todd M. PopeExecutive Officer, Director
- William N. StarlingDirector
- Dennis DoughertyDirector
- David MilneDirector
- Matt RiekeDirector
- Offering amount
- $16M
- Amount sold
- $15.2M
- First sale
- Nov 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does TransEnterix do?
- Asensus Surgical (formerly TransEnterix) develops robotic-assisted surgical systems and augmented intelligence technology, including reusable instruments, to give surgeons real-time information during procedures. Its products serve surgeons and hospitals in the operating room across international markets.
- Who are TransEnterix's investors?
- TransEnterix's investors include Aisling Capital, Saints Capital, SV Health Investors, Quaker BioVentures, SV Life Sciences.
- How much funding has TransEnterix raised?
- TransEnterix has disclosed $24.6M raised across 4 of its 5 known rounds.
- Where is TransEnterix headquartered?
- TransEnterix is headquartered in Morrisville, US.